Anti-Puma gamma/GPR109A antibody,Abcam,AB198693

Host

Rabbit

Reactivity

Human

Application

IHC-P

Platform ID

BAB886197623

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-Puma gamma/GPR109A antibody
Cat. No.AB198693
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationIHC-P
ClonalityPolyclonal
Concentration0.6 mg/mL Batch dependent concentration
ImmunogenSynthetic Peptide within Human HCAR2. The exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Immunogen
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.05% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine)
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide. See full target information HCAR2

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.